Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam
- 12 February 2007
- journal article
- research article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 31 (4) , 604-611
Abstract
Background: Benzodiazepines are the standard pharmacotherapies for ethanol detoxification, but concerns about their abuse potential and negative effects upon the transition to alcohol abstinence drive the search for new treatments. Glutamatergic activation and glutamate receptor up‐regulation contribute to ethanol dependence and withdrawal. This study compared 3 antiglutamatergic strategies for ethanol detoxification with placebo and to the benzodiazepine, diazepam: the glutamate release inhibitor, lamotrigine; the N‐methyl‐d‐aspartate glutamate receptor antagonist, memantine; and the AMPA/kainite receptor inhibitor, topiramate.Methods: This placebo‐controlled randomized single‐blinded psychopharmacology trial studied male alcohol‐dependent inpatients (n=127) with clinically significant alcohol withdrawal symptoms. Subjects were assigned to 1 of 5 treatments for 7 days: placebo, diazepam 10 mg TID, lamotrigine 25 mg QID, memantine 10 mg TID, or topiramate 25 mg QID. Additional diazepam was administered when the assigned medication failed to suppress withdrawal symptoms adequately.Results: All active medications significantly reduced observer‐rated and self‐rated withdrawal severity, dysphoric mood, and supplementary diazepam administration compared with placebo. The active medications did not differ from diazepam.Conclusions: This study provides the first systematic clinical evidence supporting the efficacy of a number of antiglutamatergic approaches for treating alcohol withdrawal symptoms. These data support the hypothesis that glutamatergic activation contributes to human alcohol withdrawal. Definitive studies of each of these medications are now needed to further evaluate their effectiveness in treating alcohol withdrawal.Keywords
This publication has 48 references indexed in Scilit:
- Benzodiazepines for alcohol withdrawal2005
- Development of Novel Pharmacotherapies for the Treatment of Alcohol Dependence: Focus on AntiepilepticsAlcohol, Clinical and Experimental Research, 2004
- Hormonally regulated α4β2δ GABAA receptors are a target for alcoholNature Neuroscience, 2002
- Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists - in vitro characterisationAmino Acids, 2000
- Concentration—Effect Studies with Topiramate on Selected Enzymes and Intermediates of the GABA ShuntEpilepsia, 2000
- Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neuronsSynapse, 1996
- Glutamate receptors in alcohol withdrawal-induced neurotoxicityMetabolic Brain Disease, 1995
- NMDA Receptors: Role in Ethanol Withdrawal SeizuresAnnals of the New York Academy of Sciences, 1992
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Multiple Comparison Procedure for Comparing Several Treatments with a ControlJournal of the American Statistical Association, 1955